News Image

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Provided By GlobeNewswire

Last update: Nov 15, 2024

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial

Overall, in Cohort A1, 25% of patients achieved functional cure

Read more at globenewswire.com

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (12/12/2025, 8:12:46 PM)

After market: 4.75 +0.04 (+0.85%)

4.71

+0.04 (+0.86%)



Find more stocks in the Stock Screener

Follow ChartMill for more